About Us

MABT’s current mission is to implement our proprietary therapy technology, IMT504. We are close to a medical breakthrough with Rabies and are concentrating on developing next generation COVID-19 vaccines.

MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.

We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as Rabies and COVID-19.

Rabies represents a unique unmet medical need, for which there is no effective therapy. When Rabies virus gets in the brain, it is the most lethal organism known to the medical community, with a fatality rate of essentially 100%. Rabies is a devastating world problem. Annual deaths worldwide are numerous. In the past 40 years, estimated deaths are over 3 Million people!

In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity.

We are developing second generation COVID-19 vaccines through our wholly owned subsidiary, NidoVax. We believe that our vaccines will afford broad protection against the numerous viral variants threatening our world.

Press

Click below to see Press Release


Research

IMT504

IMT504 is a novel, patented immunotherapy that has shown robust results in testing 

Immunotherapy

Our approach to combating bacteria and viruses can revolutionize medical care

Rabies

Rabies is the world’s most lethal disease, killing virtually 100% of brain-infected patients

COVID-19

COVID-19 is the greatest medical threat the world is currently facing. 

Executive Team

Leadership

CEO and Founder: David Horn, M.D., F.A.C.P., F.I.D.S.A.
Dr. Horn brings over 30 years of research expertise in infectious diseases and is board-certified in internal medicine and infectious diseases. Prior to founding Mid-Atlantic Biotherapeutics, Dr. Horn held senior positions in Medical Services and Clinical Development at Merck & Co., Inc., and Professional Services and Medical Affairs at Bristol-Myers Squibb. Dr. Horn has also provided specialty consultancy services to many of the leading pharmaceutical companies. Dr. Horn has designed and performed Phase I-IV clinical trials, and serves on various technology assessment committees. Dr. Horn is board-certified in Internal Medicine and Infectious Diseases, and a fellow of both the American College of Physicians, and the Infectious Disease Society of America. He has authored or co-authored publications concerning HIV infection and AIDS, fungal diseases, bacterial infections, tuberculosis, medical informatics and sepsis.

President and Co-Founder: David Jobes, Ph.D.
Dr. Jobes brings over 20 years of research and business development expertise in virology and HIV. Dr. Jobes received his Ph.D. in cell and molecular biology from Tulane University. After completing his postdoctoral training at the NIH, Dr. Jobes worked at Applied Biosystems, where he was integrally involved in bringing a novel HIV drug resistance kit to market, ViroSeq®. He then moved to VaxGen where he ran a research group that characterized the HIV strains isolated from VaxGen’s two international Phase 3 HIV vaccine trials. This work has resulted in numerous publications studying the effects of the vaccines in MSMs and IV drug users. Prior to founding Mid-Atlantic Biotherapeutics, David was a co-founder of Presidio Pharmaceuticals, a small molecule HIV and HCV therapeutic company, whose lead compound is now in Phase 1 clinical trials.

Senior VP of Operations and Co-Founder: Jean-Pierre Gagnon, Ed.D.
Dr. Gagnon has over 35 years of executive experience in U.S. and International Sales & Marketing, Commercial (P&L) Operations (including President – Merck Mexico). During his career at Merck, Dr. Gagnon was the architect for the launches of several multi-billion dollar brands in the US and led large commercial organizations in Canada, US and Latin America. Dr. Gagnon led the launches and the commercialization of the most successful vaccines and anti-infective brands created by Merck over the last 25 years. In 2013, he graduated with a doctoral degree in Global Business Leadership from the University of Pennsylvania (in collaboration with the Wharton Business School and Thunderbird University). Over the years, Dr. Gagnon has developed an extensive global network of thought leaders, business leaders, human and animal health experts, practitioners, and academicians.


IMT504 Super Charges your own Immune System

Technology

IMT504 is a novel oligodeoxynucleotide immunotherapy that has shown robust results in numerous animal safety and efficacy models, as well as in humans. Recent data suggest that IMT504 will be a highly effective therapy for addressing Rabies and COVID-19. Additional exciting data suggests that the IMT504 platform could be an effective treatment for other diseases too. 

IMT504 is our proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response. IMT504 has the ability to address emergency situations like the current COVID-19 pandemic.